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tis, which contrasts with the high frequency of the-
se antibodies in RA/sSS. These results suggest that
anti-CCP-Abs could be useful in the distinction
between pSS and RA with sSS. Although not useful
for the differential diagnosis between RA and pSS,
RFs may have a prognostic role in pSS.
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Introduction
Primary Sjögren’s Syndrome (pSS) is a systemic au-
toimmune rheumatic disease characterized by
lymphocitic infiltration and dysfunction of exocri-
ne glands,1 causing xerostomia and xerophtalmia.
Extraglandular involvement is frequent and inclu-
des non-erosive arthritis2 that may be deforming
and present a distribution similar to rheumatoid
arthritis (RA), which can lead to difficulties in its
discrimination from secondary Sjögren’s syndro-
me (sSS) associated with RA.
Several autoantibodies are associated with pSS,3
of which the most frequent are anti-SSA, anti-SSB
antibodies, and RFs. The detection of RFs in a high
percentage of pSS patients could be another obs-
tacle for the distinction between RA and pSS, espe-
cially in patients with polyarthritis. The identifica-
tion of anti-CCP-Abs and its recognition as an im-
portant diagnostic tool in RA4, 5 is helpful in the dif-
ferential diagnosis betwen RA and other rheumatic
diseases. However, although highly specific for RA,
anti-CCP-Abs have been described in low fre-
quency associated with diseases such as psoriatic
arthritis,6 systemic lupus erythematosus,7 mixed
connective tissue disease,8 systemic sclerosis,9 as
well as in pSS.10
Our purpose was to evaluate the prevalence of
anti-CCP-Abs and RFs (anti-Human and Rabbit
IgG) of IgM and IgA isotypes in pSS and to establish
their correlation with clinical and laboratorial data.
Abstract
Objectives: The purpose of this study was to eva-
luate the prevalence and clinical significance of
anti-cyclic citrullinated peptide antibodies (anti-
CCP-Abs), IgM and IgA rheumatoid factors (RFs) in
primary Sjögren’s Syndrome (pSS).
Materials and Methods: We compared clinical and
serological characteristics of 31 pSS and 31 Rheu-
matoid Arthritis (RA) patients. Both, anti-CCP-Abs
and RFs (IgM, IgA) directed against Fc determi-
nants of IgG from humans and rabbit were detec-
ted by enzyme-linked immunosorbent assay (ELI-
SA). We included 31 blood donors as control group
for the evaluation of RFs and anti-CCP-Abs. Nine
(29%) pSS patients presented arthritis, and 10
(32,3%) RA patients also had secondary Sjögren’s
syndrome (sSS)
Results: IgM and IgA RFs prevalence was similar in
pSS and RA, whichever the antigene (Human or
Rabbit IgG) used. However, RA patients with sSS
showed a tendency to present more often RF posi-
tivity, longer disease duration and higher ESR and
CRP when compared with pSS patients with arthri-
tis. Anti-CCP-Abs were detected in 64,5% of RA pa-
tients and in only 6,9% of pSS patients (p<0,0005).
Anti-CCP-Abs were more often positive in RA pa-
tients with sSS (RA/sSS) (8 patients, 80%) than in RA
patients without sSS (18 patients, 58,1%), and were
absent in pSS patients with arthritis. RF-positive
pSS patients presented more often pulmonary in-
volvement and higher inflammatory parameters,
and less often neuropathy compared to RF-negati-
ve patients. In controls, anti-CCP-Abs were absent
and RFs were negligible.
Conclusions: Anti-CCP-Abs were detected in only
a few pSS patients, none of whom presented arthri-
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Materials and Methods
Patients
The study included a total of 93 individuals: 31 pSS
patients (all female, with mean age ± SD of 55,6 ±
13,1 years and disease duration of 8,8±7,7 years),
31 RA patients (96,8% [30/31] women, with mean
age ± SD of 57,9 ± 12,0 years and disease duration
of 10,8 ± 9,2 years). There were 10 RA patients with
sSS (32,3%), and 9 pSS patients with non-erosive
arthritis (29,0%) (5 with polyarthritis and 4 with
oligoarthritis). In pSS patients, mean ESR was 35,8
mm (SD= 20,4), whereas in RA it was 37,1 mm 
(± 29,3) (p=0,620). Mean CRP was 5,67 g/l
(SD=10,2) in pSS and 14,35 g/l (± 20,8) in RA pa-
tients (p=0,025). Leukopenia (defined as a leuko-
cyte count bellow 4000 cells/mm3) was present in
9 patients with pSS (29,0%) and in only 1 RA patient
(3,3%) (p=0,007). Systemic involvement, other than
sSS in RA and arthritis in pSS, occured in 11 pSS
(35,5%) and in 10 RA patients (32,3%).
Sjögren´s syndrome, either primary or secon-
dary, was defined according to the American-Eu-
ropean Consensus Group diagnostic criteria,11 and
RA was defined according to the American Colle-
ge of Rheumatology criteria.12 Thirty one (31)
healthy controls (blood donors), matched by age
and sex (100% female) were also analized. All pa-
tients were followed in a single Rheumatologic Ins-
titution. Clinical and epidemiological data were
collected retrospectively from each patient. 
Anti-CCP Abs and RFs detection
The measurement of anti-CCP-Abs was done 
using an ELISA kit (Quanta LiteTM CCP3, INOVA
Diagnostics, Inc. San Diego, CA), with a cut-off va-
lue of 60 U/ml. Commercial ELISA assays were also
used to detect IgM-IgA RFs anti-Human IgG (Or-
gentec Diagnostika GmbH) and anti-Rabbit IgG
(Quanta LiteTM, INOVA Diagnostics, Inc. San Die-
go, CA). On the evaluation of RFs anti-Human IgG,
serum samples with a value of 50 U/ml were con-
sidered positive. For RFs anti- Rabbit IgG, the cut
off value was 12 U/ml.
All serum samples were evaluated in duplicate.
A laboratorial screening consisting of complete
blood count, CRP and ESR was performed to each
patient when colecting the blood samples for the
immunological assays.
Statistical analysis
Qualitative values between the groups were com-
pared by the χ2 test and quantitative values by the
non-parametric Mann-Whitney test using SPSS
version 13.0 (SPSS Inc., Chicago, IL). Significance
was assumed at p<0,05.
Results
The anti-CCP-Abs were positive in 20 RA patients
(64,5%), compared with only 2 (6,9%) pSS patients
(p<0,0005) and none in the control group
(p<0,0005) (Table I). None of the pSS patients with
arthritis was anti-CCP-Abs-positive, which con-
trasts with the RA/sSS patients, of whom 80% pre-
sented anti-CCP-Abs positivity (0% vs. 80%;
p=0,001) (Table II). In RA patients the presence of
sSS was associated with increased prevalence of
anti-CCP-Abs when compared with RA patients
without sSS (80,0% vs. 57,1%; p= 0,214).
On what concerns to the RFs evaluation, we
found the following results: comparing the pSS and
RA patients to the healthy controls, we observed
that IgM-RFs were not detected in controls and
only one blood donor was IgA-RF positive
(p<0,0005). Between patients with pSS and RA, the-
re were no significant differences for both IgA and
IgM classes of RF using either human IgG or Rab-
bit IgG as antigen (Table I).
Primary Sjögren’s syndrome patients having
arthritis were compared with RA patients associa-
ted with sSS. RFs of both IgA and IgM classes were
more often positive in RA/sSS patients than in
pSS/arthritis patients (Table II), being IgM anti-
-Rabbit IgG RF levels significantly higher (37,5%
vs. 90,0%; p=0,019). In adition to a greater RF po-
sitivity, RA/sSS patients also tended to be older,
present longer disease duration, and higher in-
flammatory parameters – ESR of 42,0 mm vs. 51,1
mm and CRP of 11,0 vs. 3,1 mg/l (p=0,022) – when
compared to pSS/arthritis patients.
We evaluated the clinical and laboratory data of
pSS patients according to the presence of RFs (IgM,
IgA) anti-Human IgG as well as anti-Rabbit IgG
(Table III). We found higher levels of inflammatory
parameters – ESR and CRP – in RF-positive pa-
tients, whichever the antigen used, being particu-
larly significant the association of increased ESR
with anti-Human IgG RF positivity (p=0,034 for the
IgM RF and p=0,001 for the IgA RF).
Peripheral neuropathy correlated negatively
with the presence of IgM RF, either anti-Human
IgG (0% vs. 20,0%; p=0,060) or anti-Rabbit IgG (0%
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vs. 23,1%; p=0,042), whereas IgA RF did not appe-
ar to have any influence. Pulmonary involvement
was more frequent in RF-positive pSS patients
compared with RF-negative patients, with IgA-RF
anti-Human IgG achieving statistical significance
(29,4% vs. 0%; p=0,027).
Interestingly, we did not observe in pSS patients
any association between the presence of arthritis
and RFs specific for human and animal antigens.
Discussion
In clinical practice the distinction between pSS and
RA is of great importance, and since both diseases
share clinical and serological characteristics, relia-
ble diagnostic tools are needed.
Our population of pSS had clinical and labora-
tory characteristics similar to other published se-
ries of patients with pSS.13
We found anti-CCP Abs in 6,9% pSS patients.
Our data are in agreement to other authors who
also detected these antibodies in pSS. Goëb et al14
found anti-CCP Abs in only 4% of 137 women and
18% of 11 men with pSS. Gottenberg et al10 in a co-
hort of 134 patients with pSS found that 7,5% of the
samples were positive for anti-CCP Abs. Atzeni et
al15 recently reported that 10% of 141 individuals
with pSS were positive for those Abs. We have to
point out that none of our patients with anti-CCP
Abs had arthritis. Maybe in the future these pa-
tients will develop RA. It is described that these an-
tibodies can appear some years before the deve-
lopment of RA symptoms (Nielen et al).16 Atzeni et
al15 also suggested that anti-CCP positivity in pa-
tients with pSS may be a predictor of future pro-
gress to RA.
Anti-CCP Abs were detected in 64,5% of RA pa-
tients. The differences between RA patients and
the other groups were highly significant (p< 0,0005
vs pSS; p< 0,0005 vs controls). Our data are in
agreement to other authors4,5 who demonstrated
that anti-CCP Abs are specific markers
for RA. In RA patients, anti-CCP-Abs
were more frequent in those with sSS
than in those without sSS, however the
difference was not statisticaly signifi-
cant. We do not know if this result
would be the same if we had a higher
sample.
As expected, RFs of both isotypes
were significantly more frequent in pa-
tients than in controls. On the other
hand, there were no significant diffe-
rences of IgM and IgA RFs between pSS
and RA patients. However, IgM anti-
Rabbit IgG RF was more frequently de-
tected in RA than in pSS (74,2 vs 55,2%),
although not reaching statistical signi-
ficance (p=0,123). There are authors
Table I. Prevalence of anti-CCP-Abs and IgM and IgA RFs in patients and controls (χ2 test)
pSS vs RA vs 
pSS RA Controls pSS vs RA controls controls
n (%) n (%) n (%) p p P
IgM RF anti-Human IgG 16 (51,6) 17 (54,8) 0 (0) 0,799 <0,0005 <0,0005
IgA RF anti-Human IgG 17 (54,8) 18 (58,1) 1 (3,2) 0,798 <0,0005 <0,0005
IgM RF anti-Rabbit IgG 16 (51,6) 23 (74,2) 0 (0) 0,123 <0,0005 <0,0005
IgA RF anti-Rabbit IgG 24 (80,0) 23 (74,2) 2 (6,5) 0,590 <0,0005 <0,0005
Anti-CCP-Abs 2 (6,9) 20 (64,5) 0 (0) <0,0005 0,137 <0,0005




Age (years) 56,3±10,8 62,0±8,8 0,243
Evolution (years) 9,2±7,3 13,8±12,5 0,541
ESR (mm) 42,0±27,4 51,1±31,4 0,829
CRP (mg/l) 3,1±3,2 11,0±11,2 0,022
Leukopenia 2 (22,2%) 1 (11,1%) 0,527
IgM RF anti-Human IgG 4 (44,4%) 6 (60%) 0,498
IgA RF anti-Human IgG 5 (55,6%) 7 (70%) 0,515
IgM RF anti-Rabbit IgG 3 (37,5%) 9 (90%) 0,019
IgA RF anti-Rabbit IgG 7 (87,5%) 9 (90%) 0,867
Anti-CCP-Ab 0 (0%) 8 (80%) 0,001
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who reported that Rabbit IgG is more specific for
RA.17-20 Once again, we think the size of our sample
may have contributed to this result.
When we analyzed the clinical and laboratory
data in patients with RA/sSS and pSS/arthritis, we
found that RA/sSS patients were older and had
higher ESR and CRP. The RFs of IgM and IgA iso-
types were also more prevalent in AR/sSS patients
than in pSS/arthritis, particularly IgM anti-Rabbit
IgG RFs (90,0 vs 75,5%; p=0,022). This result is also
in agreement to what we have mencioned above,
RFs anti-Rabbit IgG are more specific for RA.
Although RFs of either IgM or IgA isotypes are not
a reliable diagnostic tool to differenciate pSS and RA,
they do seem to have clinical implications in pSS.21
Inflammatory parameters, namely ESR and CRP
were higher in RF-positive patients, with IgM and IgA
anti-Human IgG RF-positive pSS patients having sig-
nificantly higher ESR than RF-negative pSS patients.
RF-positive pSS patients had more frequently pul-
monary involvement than RF-negative patients, 
although statistical significance was only found in
the positivity to IgA anti-Human IgG RF (29,4 vs 0%;
p=0,027). Lung involvement in pSS was also repor-
ted by Atzeni et al15 in 13% of patients with pSS.
However, they did not find any correlation between
RF titers and extra-glandular involvement. This dis-
crepancy may be explained by the fact we used dif-
ferent methods for RF detection. The immunone-
phelometry does not detected IgA RFs.
In our study, RF-positive pSS patients presented
less frequently peripheral neuropathy, although
only 3 cases were reported. Neuropathy was parti-
cularly less frequent in IgM RF-positive patients,
either anti-Rabbit-IgG (0 vs 23,1%; p=0,042) or
anti-Human IgG (0 vs 20,0%; p=0,060). It is no-
teworthy to refer that RF positivity in pSS patients
was not related with the presence of arthritis.
As already mencioned, the differential diagno-
sis between pSS and RA is very important. The re-
sults of this study showed that anti-CCP-Abs were
rarely present in pSS patients. This serological
marker seems to help to descriminate between pSS
patients and RA patients with sSS. We can not rule
out the possibility that pSS patients with anti-CCP
Abs may develop RA, especially in patients who are
also positive for IgM and/or IgA RFs. These patients
must have a clinical and radiographic follow up.
Our study also suggests that, as occurs in RA,22 RFs
can have a prognostic role in pSS. Although the
small size of our sample, our results are compara-
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